Business
Operations Update
Operations Update.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n \n17 June 2024\n \nHemogenyx Pharmaceuticals plc \n(\"Hemogenyx Pharmaceuticals\" or the \"Company\")\nOperations Update\n \nHemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.\n1. HEMO-CAR-T\nClinical Trials Progress:\n· Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the implementation of clinical trials.\n· Clinical Site Setup: The setup of clinical sites at the University of Pennsylvania (\"PENN\") and the new medical centre is underway. This multi-step process involves thorough internal reviews by the science review committee and the internal review board of both clinical sites, as well as budget negotiations and logistics planning. The Company continues to work with Prevail Infoworks, a contract research organization (\"CRO\"), to manage and oversee the planning for the clinical trials.\nExpansion into Pediatric Indications:\nPediatric AML and ALL: The Company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia (\"AML\") and a subset of pediatric acute lymphoblastic leukemia (\"ALL\") patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern, and there is an urgent need for effective treatments for these conditions, which the Company believes HEMO-CAR-T will be able to provide.\n2. Chimeric Bait Receptor (\"CBR\") Platform\nThe Company's CBR platform is an advanced immunotherapy designed to reprogram or redirect innate immune cells, such as macrophages, to prevent and combat infections from both existing and emerging viral threats, as well as to eliminate specific types of cancer.\nDevelopment and Testing:\n· CBR Constructs: Scientists at Hemogenyx Pharmaceuticals are developing and testing multiple CBR constructs to identify the best candidates for t...